Drug Profile

CVI VZV 001

Alternative Names: CVI-VZV-001

Latest Information Update: 25 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cha Vaccine Institute
Class Synthetic vaccines; Varicella vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Herpes zoster

Most Recent Events

25 Mar 2026 CHA Vaccine Institute plans a phase II trial for Herpes Zoster (Prevention, In adults, In elderly) in South Korea (IM) in April 2026 (NCT07481604)
13 Oct 2023 Ministry of Food and Drug Safety of South Korea approves changes in the IND application for phase I trials of CVI VZV 001 in prevention of Herpes zoster infections
15 Mar 2023 Phase-I clinical trials in Herpes zoster (Prevention) in South Korea (IM) (NCT06137755)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com